KDR and colorectal cancer: Together with the assumption, that 2a, 2b and 3a might be VEGFR-2 inhibitors similar to previously published thienyl analogs, these promising results from tests with HCT-116 colorectal cancer cells prompted us to study the anti-angiogenic activity of compounds 2a, 2b and 3a as a possible mode of action [13].